Subscribe to RSS
![](/products/assets/desktop/img/oa-logo.png)
DOI: 10.1055/s-0043-1763493
Cervical Cancer Screening with DNA-HPV Testing and Precancerous Lesions Detection: A Brazilian Population-based Demonstration Study
Rastreamento do câncer do colo do útero com teste de DNA-HPV e detecção de lesões precursoras: um estudo de demonstração de base populacional brasileiro![](https://www.thieme-connect.de/media/10.1055-s-00030576/202301/lookinside/thumbnails/10-1055-s-0043-1763493_220262-1.jpg)
Abstract
Objective To evaluate the rates of precancerous lesions, colposcopy referral, and positive predictive value (PPV) by age groups of a population-based screening with DNA-HPV testing.
Methods The present demonstration study compared 16,384 HPV tests performed in the first 30 months of the program with 19,992 women tested in the cytology screening. The colposcopy referral rate and PPV for CIN2+ and CIN3+ by age group and screening program were compared. The statistical analysis used the chi-squared test and odds ratio (OR) with 95% confidence interval (95%CI).
Results The HPV tests were 3.26% positive for HPV16-HPV18 and 9.92% positive for 12 other HPVs with a 3.7 times higher colposcopy referral rate than the cytology program, which had 1.68% abnormalities. Human Papillomavirus testing detected 103 CIN2, 89 CIN3, and one AIS, compared with 24 CIN2 and 54 CIN3 detected by cytology (p < 0.0001). The age group between 25 and 29 years old screened by HPV testing had 2.4 to 3.0 times more positivity, 13.0% colposcopy referral, twice more than women aged 30 to 39 years old (7.7%; p < 0.0001), and detected 20 CIN3 and 3 early-stage cancer versus 9 CIN3 and no cancer by cytology screening (CIN3 OR= 2.10; 95%CI: 0.91–5.25; p = 0.043). The PPV of colposcopy for CIN2+ ranged from 29.5 to 41.0% in the HPV testing program.
Conclusion There was a significant increase in detections of cervix precancerous lesions in a short period of screening with HPV testing. In women < 30 years old, the HPV testing exhibited more positivity, high colposcopy referral rate, similar colposcopy PPV to older women, and more detection of HSIL and early-stage cervical cancer.
Resumo
Objetivo Avaliar as taxas de lesões pré-cancerosas, encaminhamento para colposcopia e valor preditivo positivo (VPP) por faixas etárias de rastreamento populacional com teste DNA-HPV.
Métodos O presente estudo de demonstração comparou 16.384 testes de HPV realizados nos primeiros 30 meses do programa com 19.992 mulheres testadas no rastreio citológico. Os programas foram comparados por taxa de encaminhamento de colposcopia e VPP para NIC2+ e NIC3+ por faixa etária. A análise estatística utilizou o teste de qui-quadrado e odds ratio (OR, na sigla em inglês) com intervalo de confiança (IC) de 95%.
Resultados Os testes de HPV foram 3,26% positivos para HPV16-HPV18 e 9,92% positivos para 12 outros HPVs, com uma taxa de encaminhamento de colposcopia 3,7 vezes maior do que o programa de citologia, que teve 1,68% de anormalidades. O teste de HPV detectou 103 NIC2, 89 NIC3 e um AIS, em comparação com 24 NIC2 e 54 NIC3 detectados por citologia (p < 0,0001). O rastreio por teste de HPV no grupo etário 25 a 29 anos teve 2,4 a 3,0 vezes mais positividade, 13,0% de encaminhamento para colposcopia, 2 vezes mais que mulheres de 30 a 39 anos (7,7%; p < 0,0001), e detectou 20 NIC3 e 3 cânceres em estágio inicial versus nove NIC3 e nenhum câncer pelo rastreio citológico (NIC3 OR= 2,10; 96%CI: 0,91–5,25; p = 0,043). O VPP da colposcopia para NIC2+ variou de 29,5 a 41,0% no programa de teste de HPV.
Conclusão Houve um aumento significativo na detecção de lesões pré-cancerosas do colo do útero em um curto período de rastreamento com teste de HPV. Em mulheres < 30 anos, o teste de HPV exibiu mais positividade, alta taxa de encaminhamento para colposcopia com VPP semelhante a mulheres mais velhas, e mais detecção de HSIL e de câncer cervical em estágio inicial.
Palavras-chave
câncer do colo do útero - infecções por papilomavírus - detecção precoce de câncer - teste de papanicolaou - teste de DNA para HPVContributions
Each author has participated actively and sufficiently in the present work, and all had final approval of the manuscript version being submitted. Teixeira J. C. contributed to the conception and design, data collection and analysis, interpretation of data, and writing of the article; Vale D. B. contributed to the conception and design, interpretation of data, and writing of the article; Disgaciatti M. G contributed to data collection, interpretation of data, and writing of the article; Campos C. S. contributed to data collection and writing of the article; Bragança J. B. contributed to the interpretation of data and writing of the article; Zeferino L. C. contributed to the conception and design, interpretation of data, and critical review of the article.
Publication History
Received: 26 August 2022
Accepted: 09 September 2022
Article published online:
06 March 2023
© 2023. Federação Brasileira de Ginecologia e Obstetrícia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)
Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil
-
References
- 1 Instituto Nacional de Câncer Jose Alencar Gomes da Silva. [Estimate 2020: cancer incidence in Brazil] [Internet]. Rio de Janeiro: INCA; 2019 [cited 2021 Jun 22]. Available from: https://www.inca.gov.br/sites/ufu.sti.inca.local/files//media/document//estimativa-2020-incidencia-de-cancer-no-brasil.pdf
- 2 Instituto Nacional de Câncer Jose Alencar Gomes da Silva. [Brazilian cervical cancer screening guidelines] [Internet]. 2a ed.. Rio de Janeiro: INCA; 2016. [cited 2021 Jun 22]. Available from: https://www.inca.gov.br/sites/ufu.sti.inca.local/files//media/document//diretrizes_para_o_rastreamento_do_cancer_do_colo_do_utero_2016_corrigido.pdf
- 3 Freitas RA, Carvasan GA, Morais SS, Zeferino LC. Excessive Pap smears due to opportunistic cervical cancer screening. Eur J Gynaecol Oncol 2008; 29 (05) 479-482
- 4 Teixeira JC, Maestri CA, Machado HDC, Zeferino LC, Carvalho NS. Cervical cancer registered in two developed regions from Brazil: upper limit of reachable results from opportunistic screening. Rev Bras Ginecol Obstet 2018; 40 (06) 347-353 DOI: 10.1055/s-0038-1660841.
- 5 Vale DB, Menin TL, Bragança JF, Teixeira JC, Cavalcante LA, Zeferino LC. Estimating the public health impact of a national guideline on cervical cancer screening: an audit study of a program in Campinas, Brazil. BMC Public Health 2019; 19 (01) 1492 DOI: 10.1186/s12889-019-7846-2.
- 6 World Health Organization. WHO guidelines for screening and treatment of precancerous lesions for cervical cancer prevention. Geneva: World Health Organization; 2013
- 7 Kitchener HC, Almonte M, Thomson C, Wheeler P, Sargent A, Stoykova B. et al. HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial. Lancet Oncol 2009; 10 (07) 672-682 DOI: 10.1016/S1470-2045(09)70156-1.
- 8 Chrysostomou AC, Stylianou DC, Constantinidou A, Kostrikis LG. Cervical cancer screening programs in Europe: the transition towards HPV vaccination and population-based HPV testing. Viruses 2018; 10 (12) 729 DOI: 10.3390/v10120729.
- 9 Koliopoulos G, Nyaga VN, Santesso N, Bryant A, Martin-Hirsch PPI, Mustafa RA. et al. Cytology versus HPV testing for cervical cancer screening in the general population. Cochrane Database Syst Rev 2017; 8 (08) CD008587 DOI: 10.1002/14651858.CD008587.pub2.
- 10 Teixeira JC, Vale DB, Bragança JF, Campos CS, Discacciati MG, Zeferino LC. Cervical cancer screening program based on primary DNA-HPV testing in a Brazilian city: a cost-effectiveness study protocol. BMC Public Health 2020; 20 (01) 576 DOI: 10.1186/s12889-020-08688-4.
- 11 Vale DB, Silva MT, Discacciati MG, Polegatto I, Teixeira JC, Zeferino LC. Is the HPV-test more cost-effective than cytology in cervical cancer screening? An economic analysis from a middle-income country. PLoS One 2021; 16 (05) e0251688 DOI: 10.1371/journal.pone.0251688.
- 12 Teixeira JC, Vale DB, Campos CS, Bragança JF, Discacciati MG, Zeferino LC. Organization of cervical cancer screening with DNA-HPV testing impact on early-stage cancer detection: a population-based demonstration study in a Brazilian city. Lancet Reg Health Am 2022; 5: 100084 DOI: 10.1016/j.lana.2021.100084.
- 13 Ministério da Saúde. Agência Nacional de Saúde Suplementar. [Sector Data and Indicators] [Internet]. 2021 [cited 2022 May 10]. Available from: https://www.gov.br/ans/pt-br/acesso-a-informacao/perfil-do-setor/dados-e-indicadores-do-setor
- 14 Fundação Sistema Estadual de Análise de Dados. [Filtered by city “Indaiatuba”, year “2020”, population “women”, and age-group “25 to 64 year”] [Internet]. 2019 [cited 2019 Nov 25]. Available from: http://produtos.seade.gov.br/produtos/projpop/index.php
- 15 Wright TC, Stoler MH, Behrens CM, Sharma A, Zhang G, Wright TL. Primary cervical cancer screening with human papillomavirus: end of study results from the ATHENA study using HPV as the first-line screening test. Gynecol Oncol 2015; 136 (02) 189-197 DOI: 10.1016/j.ygyno.2014.11.076.
- 16 Birdsong GG, Davey DD. Specimen adequacy. In: Nayar R, Wilbur DC. editors. The Bethesda System for reporting cervical cytology: definitions, criteria, and explanatory notes. 3rd ed.. Cham: Springer; 2015: 1-28
- 17 City Hall of Indaiatuba. Municipal Secretariat for Legal Affairs. Department of Legislative Technique. [Law No. 7.255, 2019 Nov 20]. The “HPV Vaccination Week” is instituted in the municipality of Indaiatuba [Internet]. 2019 [cited 2019 Nov 25]. Available from: https://sapl.indaiatuba.sp.leg.br/pysc/download_norma_pysc?cod_norma=6329&texto_original=1
- 18 Bouvard V, Wentzensen N, Mackie A, Berkhof J, Brotherton J, Giorgi-Rossi P. et al. The IARC perspective on cervical cancer screening. N Engl J Med 2021; 385 (20) 1908-1918 DOI: 10.1056/NEJMsr2030640.
- 19 McIndoe WA, McLean MR, Jones RW, Mullins PR. The invasive potential of carcinoma in situ of the cervix. Obstet Gynecol 1984; 64 (04) 451-458
- 20 McCredie MR, Sharples KJ, Paul C, Baranyai J, Medley G, Jones RW. et al. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol 2008; 9 (05) 425-434 DOI: 10.1016/S1470-2045(08)70103-7.
- 21 Arrossi S, Paolino M, Laudi R, Gago J, Campanera A, Marin O. et al. Programmatic human papillomavirus testing in cervical cancer prevention in the Jujuy Demonstration Project in Argentina: a population-based, before-and-after retrospective cohort study. Lancet Glob Health 2019; 7 (06) e772-e783 DOI: 10.1016/S2214-109X(19)30048-8.
- 22 Ronco G, Giorgi Rossi P. Role of HPV DNA testing in modern gynaecological practice. Best Pract Res Clin Obstet Gynaecol 2018; 47: 107-118 DOI: 10.1016/j.bpobgyn.2017.08.002.
- 23 Gilham C, Sargent A, Kitchener HC, Peto J. HPV testing compared with routine cytology in cervical screening: long-term follow-up of ARTISTIC RCT. Health Technol Assess 2019; 23 (28) 1-44 DOI: 10.3310/hta23280.
- 24 Hamers FF, Poullié AI, Arbyn M. Updated evidence-based recommendations for cervical cancer screening in France. Eur J Cancer Prev 2022; 31 (03) 279-286 DOI: 10.1097/CEJ.0000000000000701.
- 25 Simms KT, Hall M, Smith MA, Lew J-B, Hughes S, Yuill S. et al. Optimal management strategies for primary HPV testing for cervical screening: cost-effectiveness evaluation for the National Cervical Screening Program in Australia. PLoS One 2017; 12 (01) e0163509 DOI: 10.1371/journal.pone.0163509.
- 26 Rebolj M, Mathews CS, Pesola F, Cuschieri K, Denton K, Kitchener H. HPV Pilot Steering Group. Age-specific outcomes from the first round of HPV screening in unvaccinated women: Observational study from the English cervical screening pilot. BJOG 2022; 129 (08) 1278-1288 DOI: 10.1111/1471-0528.17058.